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Abstract: Back g rou nd: Th e older population is very heterogeneous with regard to the co-morbidity and 
the physical reserve. Th is can result in unacceptably high postoperative complications rates. Th erefore, 
the aim of the study was to review the literature regarding the outcomes of older patients treated for 
pancreatic cancer, including the usage of minimal invasive techniques.
Met hodolog y: A review of the literature was carried out including studies on pancreatic cancer in older 
patients published between 2011 and 2016. 
Re su l t s: Seventeen retrospective studies were included. Th e total number of patients was 9981 with 
the age range of 65 years and more. Studies on surgical treatment alone (1.4%), neoadjuvant/adjuvant 
treatment with or without surgery (89.4%) and palliative therapy (9.2%) were assessed separately. 
Appropriate comparison was diffi  cult due to the retrospective character and heterogeneity of the study 
population. Mortality was low, yet there was a great diff erence in morbidity ranging from some percent 
to even 100% of the study population. Long-term results were poor. 
C onc lu s ions: Th e functional status, not the chronological age alone, is the factor limiting therapeutic 
options in older patients with pancreatic cancer.
Key words: cancer, pancreas, elderly, outcomes.
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Introduction
Pancreatic cancer is the seventh most common cause of cancer-related death 
worldwide and the incidence rate is increasing [1]. Of the many factors infl uencing 
this condition the most important is the ageing of the society. Higher life expectancy 
gives opportunity to develop cancer disease [2–23]. 
However, the older population is very heterogeneous with regard to the 
co-morbidity and the physical reserve, which makes some of them very vulnerable 
to stressors, such as surgery. This can result in unacceptably high postoperative 
complications rates. Th erefore, it is necessary to provide a  comprehensive review of 
the literature regarding the outcomes of older patients treated for pancreatic cancer.
Materials and Methods
In January 2017, a  review of the literature was carried out including studies on 
pancreatic cancer in older patients published in the Pubmed database between 2011 
and 2016. Search words were: “treatment” AND “outcome” AND “pancreatic cancer” 
AND “elderly” OR “older”. To narrow down the search –age (65+), language (English) 
and species (humans) fi lters were used. Th e literature search and study selection is 
summarized in Fig. 1.
Fig. 1. Flow chart of the study selection process.
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Results
In the review, we fi nally included 22 retrospective studies (including one retrospective 
analysis of a randomized study) on patients treated between 1990 and 2016. Th e total 
number of patients was 9981 in which 5696 (57.1%) were female and 4263 (42.7%) 
were male. In two studies (33 patients; 0.2% of all included patients) the gender was 
not mentioned. Th e median/mean age was not mentioned in most of the papers, but 
the age range was 65 years and more. Ninety seven percent (9667) of patients had 
ductal adenocarcinoma, 0.1% (7) neuroendocrine tumour and in 2.9% (307) of cases 
the tumour type was not mentioned. Th e characteristics of the included studies were 
shown in Table 1. Studies on surgical treatment alone, neoadjuvant/adjuvant treatment 
with or without surgery and palliative therapy were assessed separately. 
Table 1. Characteristics of the included studies. 
Article/authors Time of study/ publication year Type of study
No. of 
patients
Female/
Male
Mean age 
(range)
[2] Imaoka et al. 2007–2009/2016
Retrospective 
(on previous 
randomised trial)
90 37/53 74.0 (NM)
85 39/46 73.4 (NM)
86 45/41 73.6 (NM)
[3] Beltrame et al. 1998–2011/2015 Retrospective 23 12/11 82.6 (80–86)
[4] Frakes et al. 2000–2012/2015 Retrospective
35 18/17 NM (70–75)
26 15/11 NM (76–80)
26 10/16 NM (≥80)
[5] Li et al. 2005–2013/2015 Retrospective
114
133/104
NM (75–79)
84 NM (80–84)
39 NM (≥85)
[6] Jeon et al. 2007–2009/2015 Retrospective 7813 4601/3212 NM (≥65)
[7] Kinoshita et al. 2005–2012/2015 Retrospective
26 17/9 82 (80–87)
20 8/12 82 (80–88)
[8] Miura et al. 2009–2014/2015 Retrospective 36 15/21 NM (≥75)
[9] Berger et al. 2007–2012/2014 Retrospective 53 27/26 73 (70–89)
[10] Cooper et al. 2000–2008/2014 Retrospective
179 85/94
NM (≥70)
57 31/26
[11] Gangl et al. 2001–2010/2014 Retrospective 9 6/3 83 (80–91)
[12] Kanda et al. 2000–2012/2014 Retrospective
43 16/27 75 (72–78)
47 21/26 73.5 (71–76)
[13] Nagrial et al. 1990–2011/2013 Retrospective 178 99/79 75.2 (70–87)
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Article/authors Time of study/ publication year Type of study
No. of 
patients
Female/
Male
Mean age 
(range)
[14] Kizilbash et al. 1998–2005/2012 Retrospective
334 177/157
72 (≥65)
177 89/88
169 88/81
25 NM
[15] Marcovalerio et al. 1990–2009/2012 Retrospective 25 9/16 83.1 (80–89)
[16] Hatzaras et al. 1990–2007/2011 Retrospective 27 13/14 83.4 (80–91)
[17] Hentic et al. 2000–2006/2011 Retrospective
20 12/8
78 (75–84)
18 8/10
[18] Matsumoto et al. 2003–2009/2011 Retrospective
36 20/16 74 (65–86)
32 10/22 83 (66–96)
[19] Aprea et al. 2012–2015/2016 (online) Retrospective
7 5/2 73.6 (71.1–76.1)
15 10/5 73.5 (NM)
[20]  Fernandez-Cruz 
et al.* 2016/2016 Retrospective 11 7/4 73.9 (67–83)
[21] Poves et al.* 2012–2014/2015 Retrospective 4 3/2 75 (67–78)
[22]  Pavlik Marangos 
et al.* 1997–2012/2012 Retrospective 14 10/4 73.4 (66–83)
[23] Kendrick et al.* 2007–2010/2011 Retrospective 8 NM 76.6 (68–81)
* series of case reports, NM — not mentioned. 
Outcomes of surgical treatment alone
Ninety nine (1%) patients were treated with surgery alone. Th ere were 50 (50.5%) 
females and 49 (49.5%) males. Th e median age was between 73.5 and 83.4 years. 
Th e  ductal adenocarcinoma was present in 81 (81.8%) of cases and only 3 (3.0%) 
patients had neuroendocrine tumours. Th e other patients (15, 15.2%) had unknown 
histological type of tumours. Th e location and the stage of the tumour were not given in 
most of the papers. Seventy-six patients (76.8%) underwent pancreatoduodenectomy, 
including 26 (26.3%) pylorus-preserving surgery, twenty (20.2%) patients distal or 
subtotal pancreatectomy and 3 (3.0%) total pancreatectomy. Two (2.0%) patients 
had concomitant vascular resection. Th e morbidity range was from 33.3% to 68% 
of study population. In the postoperative period two deaths (2.0%) were reported as 
resulting from the procedure. Th e follow-up period was to 144 months, with mean 
follow-up period equal to 6 months for one study. Median overall survival range was 
10.5–33.3  months. Th e detailed characteristics of the studies with only the surgical 
approach are summarized in Table 2. Separate data is shown for minimal invasive 
Table 1. Cont.
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techniques in Table 3. Th ere were 44 (0.4%) patients treated by laparoscopy: twenty-fi ve 
females (56.8%), 12 (27.3%) males and 8 patients with unknown gender. Th e median 
age was from 73.4 to 76.6 years. Laparoscopic distal pancreatectomy was leading 
procedure (36, 81.8%) connected with splenectomy (28, 63.6%) and nephrectomy in 
one case. Eight (18.2%) patients underwent total laparoscopic pancreatoduodenectomy 
with major venous resection. Operative time for this procedures was between 73 and 
666 minutes. In most cases follow-up time was dictated by survival time of patients 
and it was even to 108 months. 
Outcomes of multimodal treatment
The majority of there viewed patients had combined therapy. The detailed 
characteristics of the studies are summarized in Table 4. Th ere were 8924 (89.4%) 
patients of which 5137 (57.6%) were female and 3738 (41.9%) male. Two studies 
(49  patients; 0.5%) did not mention the gender. Th e age of the included patients 
was over 65. Based on the American Joint Committee on Cancer classifi cation, there 
were 1961 (21.9%) stage I–II tumours, and 1037 (11.6%) stage III–IV tumours. More 
detailed tumour stages were reported in few of the studies. Sixty-six and half percent 
of patients did not have any information about the stage. 
Surgery was the treatment for 1874 (21.0%) patients: pancreatoduodenectomy 
(847; 45.2%) followed by partial surgery (126; 6.7% not closely defi ned by the authors), 
total pancreatectomy (41; 2.2%) and distal pancreatectomy (27; 1.4%). Concomitant 
vessel resection was performed in 86 (4.5%) patients. In 41% (768) of patients the 
type of surgery was not mentioned. Th e treatment was combined with chemotherapy 
alone in 1914 (21.4%), with chemoradiotherapy in 705 (7.9%) and radiotherapy 
alone in 606 (6.8%) patients. One study investigated the combination of the surgical 
treatment with versus without the statins, including 2544 (28.5%) patients. 
Th e morbidity range was reported to be between 42.2% and 100% of the study 
population, including 35% of patients with major complications. Th e most common 
reported complication was pancreatic fi stula (41; 0.4%) followed by wound infection 
(27; 0.3%) and other gastrointestinal problems (16; 0.2%). Seven (0.1%) patients died 
and 16 (0.2%) were readmitted. Th e follow-up time was from 48 to 106 months with 
median overall survival of 2.4–27 months. In case of one patient there was a complete 
response to the neoadjuvant treatment.
Outcomes of palliative treatment
Nine hundred sixteen (9.2%) patients received palliative treatment: 470 (51.3%) were 
female and 446 (48.7%) were male. Th e included patients were 65 or over. In most 
cases ductal adenocarcinoma was diagnosed (635; 69.3%), but for 281 (30.7%) the 
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Table 4. Summary of the studies reporting the outcomes of the multimodal treatment. 
Article/authors N (F/M) Mean age (range) Location (n) AJCC Stage (n)
[4]  Frakes et al.
35 (18/17) NM (70–75)
Head (87) I ( 5)II (11)
III (70)
IV (1)26 (15/11) NM (76–80)
26 (10/16) NM (≥80)
[6] Jeon et al.
5357
(3160/2197)
NM (≥65)
NM
I–II (718)
III–IV (640)
Unknown (3999)
2456 
(1441/1015) NM
I–II (432)
III–IV (314)
Unknown (1710)
[7]  Kinoshita et al. 26 (17/9) 82 (80–87) NM I (2) II (20)IV (4)
[8]  Miura et al. 24 (NM) NM (≥75) NM
I (9)
II (14)
Complete response (1)
[10]  Cooper et al. 179 (85/94) NM (≥70) Head (160)Body/Tail (19)
Primary resectable (153)
Borderline (26)
[12]  Kanda et al.
43 (16/27) 75 (72–78)
Ductal 
location (90)
I (1)
IIA (15)
IIB (23)
IV (2)
47 (21/26) 73.5 (71–76) I (2)IIA (10)
IIB (29)
IV (6)
[14] Kizilbash et al.
334 (177/157)
72 (65+)
Head (258)
Body/Tail (76) I (47)
IIA (84)
IIB (203)
177 (89/88) Head (144)Body/Tail (33) I (22)
IIA (38)
IIB (116)
169 (88/81) Head (121)Body/Tail (48) I (25)
IIA (35)
IIB (107)
25 (NM) NM IIB (13)Others (12)
NM — not mentioned, PD — pancreatoduodenectomy, AdenoCa — adenocarcinoma, AJCC — American 
Joint Committee on Cancer, FU — fl uorouracil.
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exact histologic type of the tumour was not given. Locally advanced tumours were 
reported in 154 (16.8%) and metastatic disease was present in 434 (47.4%) patients. Th e 
stage was unknown for 328 (35.8%) tumours. Chemotherapy was the most common 
palliative treatment modality. As the fi rst line chemotherapy, gemcitabine alone was 
used in 294 (32.1%) cases, gemcitabine combined with other regimens in 241 (26.3%) 
Table 5. Summary of the studies reporting the outcomes of the palliative treatment.
Article/authors N (F/M) Mean age (range)
Histology 
type (n) Location (n) Stage (n)
[2]  Imaoka 
et al.
90 (37/53) 74.0 (NM)
AdenoCa or 
Adenosqua- 
mous Ca
Head (33)
Body/tail (53)
Unn (4)
Locally advanced (23)
Metastases (67)
85 (39/46) 73.4 (NM)
Head (31)
Body/tail (47)
Unn (8)
Locally advanced (24)
Metastases (61)
86 (45/41) 73.6 (NM)
Head (41)
Body/tail (43)
Unn (3)
Locally advanced (28)
Metastases (58)
[5] Li et al. 
114
(133/104)
NM (75–79)
AdenoCa
Head (122)
Body/tail (112)
Unn (22)
Metastatic disease 
>70%84 NM (80–84)
39 NM (≥85)
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tumours, S1 alone (Tegafur/gimeracil/oteracil) for 88 (9.6%) patients and other 
regimens in 131 (14.3%) cases. Moreover, 3.7% of patients received chemoradiotherapy 
and 0.4% radiotherapy alone. Th e follow-up period was 36–193 months with median 
overall survival range of 1.4–21.8 months. Th e detailed characteristics of the studies 
with only the palliative approach are summarized in Table 5.
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1.4 
Gemcitabine:
Mono (35)
With erlotinib (11)
with oxaliplatin (6)
with capecitabine (6)
with carboplatin (1)
withnab-paclitaxel (1)
with 5-FU and HAI cisplatin (1)
FOLFOX (2)
FOLFIRINOX (3)
Clinical trial (4)
Unn therapy (1)
7.9 
Without 
therapy: 
2.5 
Gemcitabine:
Mono (23)
With capecitabine (1)
FOLFOX (1) 7.7 
Without 
therapy:
4.7
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Article/authors N (F/M) Mean age (range)
Histology 
type (n) Location (n) Stage (n)
[7]  Kinoshita 
et al. 20 (8/12) 82 (80–88) NM NM NM
[8]  Miura et al. 36 (15/21) 77 (NM) AdenoCa NM
Resectable (19)
Borderline resectable 
(17)
[9]  Berger et al. 53 (27/26) 73 (70–89) AdenoCa NM
Metastatic disease 
(47)
Locally advanced (6)
[10]  Cooper 
et al. 57 (31/26) NM (>70) AdenoCa
Head (50) 
Body/Tail (7)
Resectable or 
borderline
[13]  Nagrial 
et al. 178 (99/79) 75.2 (70–87) AdenoCa
Head (146) 
Body/tail (28)
AJCC
I (6)
II (169)
[17]  Hentic 
et al. 38 (20/18) 78 (75–84) AdenoCa NM
Locallyadvanced (15)
Metastaticdisease (15)
[18]  Matsumoto 
et al. 36 (16/20) 74 (65–86) AdenoCa
Head (21)
Body/Tail (15)
Locallyadvanced (16) 
Metastatic (20)
AdenoCa — adenocarcinoma, Unn — unknown, 5FU — fl uorouracil, AJCC — American Joint Committee on 
Cancer, * — median survival time.
Table 5. Cont.
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Treatment (n)
Fo
llo
w-
up
 ti
m
e 
[m
on
th
s]
 
M
ed
ia
n 
ov
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al
l 
su
rv
iv
al
 
[m
on
th
s]
 
Gemcitabine (10)
S-1 (3)
Gemcitabine+S-1 (6) → second line gemcitabine (2)
Gemcitabine+erlotinib (1)
106  11.7*
Neoadjuvant:
Chemotherapy alone (2)
Chemoradiation (24)
Chemotherapy and chemoradiation (10)
Chemotherapy regimen:
Gemcitabine alone (4) 
Gemcitabine doublet (2)
5-FU–based doublet (3)
FOLFIRINOX (3)
48 9.1 
Gemcitabine-based: (43)
Gemcitabine mono (22)
Gemcitabine/erlotinib (20)
Gemcitabine/capecitabine (1) 
FOLFIRINOX (4)
OFF (3)
Capecitabine (1)
FOLFOX (2)
Second line treatment (21)
78 6.7 
Gemcitabine + cisplatin or erlotinib 60 11.0 
Adjuvant chemotherapy (53)
193 
21.8 
No adjuvant chemo (125) 13.1
Adjuvant radiotherapy (4)
Palliative chemotherapy (35)
Global
15.8 
Gemcitabine (28) 
(Gemcitabine 1000 mg/m² as a 30-min 
infusion weekly for 7 out of 8 wk and 
then for 3 out of 4 wk)
Gemcitabine with oxaliplatin (2) 
(Gemcitabine 1000 mg/m² as 
a 100-min infusion on day 1 and 
oxaliplatin 100 mg/m² as a 2-h 
infusion on day 2 every 2 wk).
44 8.9 
Intravenous GEM infusion of 600–800 mg/m2 during a 30-min period on 
days 1, 8 and 15 of a 28-day cycle 84 7.6 
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Discussion
Outcomes of surgical treatment
Based on the current literature, the assessment of surgery outcomes in pancreatic 
cancer treatment is diffi  cult due to the constant progress in medicine and the long study 
inclusion time (1990–2011) [3, 15–16]. Twenty years time makes a huge diff erence in 
anaesthesia and postoperative care. A small group of older patients (1% of the study 
population) treated just surgically were not consecutive patients but selected. Th e 
age alone is not a  contraindication to the procedure. Two studies included patients 
at the age of 90 years and more. However, the selection process in all studies did not 
take Comprehensive Geriatric Assessment and frailty into account. Moreover, in the 
published papers there is oft en lack of data on tumour location [3, 11, 15] and its stage, 
which makes any comparison almost impossible [3, 11, 16]. Th ere is also a signifi cant 
diff erence in reported morbidity between the studies: Gangl et al. (33.3%) versus 
Marcovalerio et al. (68%). Th is should be, in the opinion of the second authors, due 
to more liberal inclusion process of patients [11, 15]. Isolated deaths can be assumed 
as a  statistical risk and did not dominate in any research, which may be a  benefi t of 
a  well-chosen group. Th e very long follow-up time was reported by the Beltrame et 
al. and Gangl et al. (120 and 144 months, respectively). However, only Gangl et al. 
showed that one patient in nine survived such a  long time [3, 11]. Moreover, there 
are diff erences in the preoperative assessment of the patients. Gangl et al. excluded 
patients with Eastern Cooperative Oncology Group 3–4 score and dementia, while in 
the case of Hatzaras et al. an interdisciplinary team was involved in patient care. Th e 
high survival rates can also be attributed to the exclusion of patients with potential 
frailty syndrome [11, 16]. Moreover, despite the fact that the number of performed 
laparoscopy increases every year, there is still only few research taking into account 
the minimally invasive techniques with a suffi  cient amount of data. We obtained only 
fi ve studies corresponding to search criteria. Furthermore, 4 of them were based on 
case report series which makes it impossible to collect all data [20–23]. However, it 
is interesting that despite similar characteristic of groups in those studies operative 
time have a  large discrepancy (73–666 minutes) [22–23]. It can be explained by 
performed a renal vein interposition graft  done in a longer case, but both authors did 
not comment this short and long operative time [22–23]. Unfortunately, all authors 
did not provide median overall survival which could be compared with open surgery, 
but morbidity and mortality seem to be similar [3, 11, 15–16, 19–23]. Aprea et al. 
compared laparoscopy and open surgery receiving shorter operative time (186.2 ± 11 
vs. 180.4 ± 7 minutes, respectively), less blood loss (212.30 ± 62 vs. 342.3 ± 104 ml) 
and shorter postoperative hospital stay (7.2 ± 1.2 vs. 11.3 ± 4 days) [19]. Chapman 
et al. obtained similar data additionally they showed that conversion worsening the 
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outcome aft er treatment [24]. Th erefore, the operator’s experience may be crucial. Th e 
learning curve of laparoscopic distal pancreatectomy showed that benefi ts are higher 
aft er 17th operated patient [25].
Aft er the process of selection of articles for review, a  meta-analysis concerning 
pancreatoduodenectomy in pancreatic head tumours in the elderly was published. In 
this publication Pędziwiatr, Małczak et al. presented a  similar level of postoperative 
complications (47.23% vs 33.3% — 68%) in the elderly, while showing a higher level 
of mortality (4.54% vs 2.0%), which may be due to the small number of groups in 
our study (number of patient respectively, 2180 vs 99) [26]. Summarising the current 
literature and mentioned meta-analysis, the chronologic age is not a contraindication 
to the surgery and in well selected older patients treated in reference centres 
low morbidity and mortality can be achieved especially with minimal invasive 
techniques. However, we do not have information on the quality of life of the 
older patients from articles selected to review, which is oft en more important than 
long survival.
Outcomes of the multimodal treatment
Th e direct comparison is very diffi  cult because in the biggest study [6] we do not have 
information on tumour stages. Moreover, the authors do not report neoadjuvant/
adjuvant regimens applied [4, 6–8, 10, 12]. Only the Kizilbash et al. give the complete 
data [14].
Th ere was a  signifi cant diff erence in the morbidity rate reported by the authors: 
from 33% to even 100%. However, in the later study (with 100% morbidity) there 
were only 8% of major complications defi ned as Clavien-Dindo III or greater [7–8]. 
Despite this, Kinoshita et al. and Miura et al. did not assess the quality of life 
(during and after treatment), which may be more important than achieving null 
mortality [7–8]. 
Jeon et al. examined anti-cancer properties of statins shown in mechanistic 
studies  [6]. Th e signifi cantly lower median survival time observed in this study is 
diffi  cult to comment on due to unknown tumour stage and lack of information on 
treatment. In most cases patients were using only statins without additional treatment. 
Summarising this study, statins reduced death rates by 7–9% but only for grade I–II 
tumours and in those who underwent surgery, prolonging the survival from 2.4 mo 
to 4.7 mo [6].
Generally, the age is not a  contraindication and a  well-chosen group may 
gain strong benefits from multimodal therapy compared to chemotherapy alone 
(27 months vs. 16.4 months) [10], especially when it is used prior to surgery (overall 
survival 27.2 months vs. 9.1–9.7 months) [8]. Beginning with the adjuvant treatment 
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could be difficult in older patients after surgery due to the general status of the 
patients and complications of the surgical treatment. In Kinoshita et al.’s study only 
6 in 26 patients fi nished the treatment [7] and two thirds of patients in Miura et al.’s 
study [8]. However, most of the studies do not report any use of Geriatric Assessment 
in the treatment process.
Outcomes of palliative treatment
Th e great majority of patients had metastatic disease at the moment of the diagnosis; 
therefore the only solution for increasing the survival of older population may 
be palliative treatment (Table 5). Th e combinations of chemotherapeutics provide 
diff erent types of treatment based mostly on gemcitabine or S1 (Tegafur/gimeracil/
oteracil)  [2,   5, 7–10, 13, 17–18]. However, many chemotherapeutics have not been 
tested in older patients with cancer due to the potential detrimental eff ect on their 
health [2].
In some studies it is diffi  cult to assess the outcome for lack of control groups 
without any treatment [7–8, 10]. It is important to realize that patients undergoing 
palliative therapy are often in a  much worse condition. Median overall survival 
was from 2.5 months to even 21.8 months, which may be promising for palliatively 
treated patients. Nagrial et al. showed evident benefi ts of receiving palliative treatment 
(21.8 months vs.13.1 months). However, this study did not show any specifi c reason 
for the lack of treatment in the second group [13].
Conclusion
Th e functional status, not the chronological age alone, is the factor limiting therapeutic 
options in older patients with pancreatic cancer. Th e mortality and morbidity in 
reference centres are low. However, currently published studies are in most cases 
retrospective and with a  great heterogeneity of the included patients, which limits 
the evidence based decision taking. Th erefore, proper Geriatric Assessment of older 
patients, preferably by a  multidisciplinary team, including a  geriatrician, should be 
a key preoperative step. Moreover, prospective studies should be carried out focusing 
not only on survival but also on the quality of life, which is oft en more important 
for older patients. Also, use of minimally invasive techniques should be properly 
examined in prospective studies, to provide suffi  cient data about outcomes of 
treatment.
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